Plain-English translation of NCT07047989 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing NWRD09, an experimental immunotherapy designed to help your body fight cervical precancer (HSIL) caused by HPV-16. You would receive four injections over 12 weeks, and researchers would carefully monitor your safety and how your immune system responds. This is an early-stage study, so the main goal is to find the safest and most effective dose.
Cervical precancer caused by HPV-16 can progress to invasive cancer if left untreated, but current treatment options are limited. This medication is being developed as a new immunotherapy approach that may help your own immune system eliminate the precancerous cells more effectively.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for injections at weeks 0, 2, 4, and 12, with follow-up safety visits continuing for 28 days after your third injection. At week 24, you would return for a colposcopy and biopsy to check how well the treatment worked. In total, the trial lasts about 6 months, and researchers will monitor your safety closely throughout.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Newish Biotech (Wuxi) Co., Ltd.
Enrollment target
~9 participants
Started
June 2025
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Sex
Female only
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yang Xiang
Newish Biotech (Wuxi) Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.